Digestive Diseases and Sciences

, Volume 31, Issue 8, pp 847–852 | Cite as

Gastric protection by meciadanol

A new synthetic flavonoid-inhibiting histidine decarboxylase
  • Stanislaw J. Konturek
  • Mary Ellen Kitler
  • Tomasz Brzozowski
  • Tadeusz Radecki
Original Articles


Flavonoids reportedly inhibit histidine decarboxylase and reduce gastric mucosal histamine content. We studied the effects of acute and chronic intragastric administration to rats of meciadanol, a new synthetic flavonoid (Zyma S.A., Nyon, Switzerland). The action of meciadanol was compared to that of 16, 16-dimethyl PGE2. Meciadanol did not affect acid or pepsin output at any dose used. High doses of 16, 16-dimethyl PGE2 reduced both acid and pepsin output. Meciadanol partially prevented aspirin-induced lesions but the prevention required chronic administration of meciadanol. In contrast, a single dose of meciadanol completely prevented ethanol-induced lesions. Chronic administration of meciadanol also completely prevented ethanol-induced lesions. 16, 16-Dimethyl PGE2 prevented both aspirin-induced and ethanol-induced lesions in doses that did not affect acid or pepsin output. Meciadanol did not influence the effect that either aspirin or ethanol had on endogenous mucosal PGI2. Thus, the dose range of meciadanol that protected against ulcerogens did not affect either gastric acid secretion or pepsin output. Therefore, we conclude that meciadanol's action represents true cytoprotection, which was previously attributed only to prostaglandins.


Histamine Flavonoid PGE2 Gastric Acid Secretion Chronic Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lorenz W, Kusche J, Berth H, Nathias CH: Action of several flavonoids on enzymes of histamine metabolismin vitro.In Histamine. C Maslinski (ed). Stroudsburg, Pennsylvania, Dowde, Hutchinsin and Ross, 1983, pp 265–269Google Scholar
  2. 2.
    Kusche J, Barth H, Schmal A, Nusimé H, Schülle G, Froelich R, Schmidt J, Raabe R: Effects of (+)-catechin on several enzymes of histamine metabolism and on stress ulcer formation in the female rat. Naunyn-Schmiedebergs Arch Pharmacol, Suppl 287:R62, 1975Google Scholar
  3. 3.
    Neugebauer E, Dietz W, Seibel I, Garcia-Caballero M, Lorenz W: Effects of several flavonoids on enzyme activity of acid (specific) histidine decarboxylase (HDC) from the gastric mucosa of mammals and man. 13th Meeting European Histamine Research Society, Florence, Italy, 1984, Agents Actions (in press)Google Scholar
  4. 4.
    Reiman HJ, Lorenz W, Fischer M, Fröhlich R, Meyer HJ: Histamine and acute hemorrhagic lesions in rat gastric mucosa: Prevention of stress ulcer formation by (+) catechin, an inhibitor of specific histidine decarboxylasein vitro. Agents Actions 7:69–73, 1977Google Scholar
  5. 5.
    Parmar NS, Ghosh MN: Gastric antiulcer activity of (+)cyanidanol-3, a histamine decarboxylase inhibitor. Eur J Pharmacol 69:25–32, 1981Google Scholar
  6. 6.
    Lane A, Ivy AC: Response of the chronic gastric fistula rat to histamine. Am J Physiol 190:221–228, 1957Google Scholar
  7. 7.
    Robert A, Nezamis JE, Lancaster C, Hanchar AJ: Cytoprotection by prostaglandins in rats: Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl and thermal injury. Gastroenterology 77:433–443, 1979Google Scholar
  8. 8.
    Konturek SJ, Piastucki I, Brzozowski T, Radecki T, Dembinska-Kiec A, Zmuda A: Role of prostaglandins in the formation of aspirin-induced gastric ulcers. Gastroenterology 80:4–9, 1981Google Scholar
  9. 9.
    Havsteen B: Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol 32:1141–1148, 1983Google Scholar
  10. 10.
    Bentrath A, Russuvan S, Szent-Györgyi A: Vitamin nature of flavones. Nature 138:798, 1936Google Scholar
  11. 11.
    Cojocaru AF, Ruzieva RH, Topaly EE, Topaly VP: Uncoupling of oxidative phosphorylation by PEA flavonoids part 1 model experiments with artificial lipid membranes. Stud Biophys 72:15–22, 1978Google Scholar
  12. 12.
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature (London), New Biol 231:232–235, 1971Google Scholar
  13. 13.
    Baumann J, Wurm G, von Bruchhausen F: Prostaglandin synthetase inhibition by flavonoids and phenolic compounds in relation to their oxygen-scavenging properties. Arch Pharm (Weinheim, Ger) 313:330–337, 1980Google Scholar
  14. 14.
    Cavallini L, Bindoli A, Siliprandi N: Comparative evaluation of antiperoxidative action of silymarin and other flavonoids. Pharmacol Res Commun 10:133–136, 1978Google Scholar
  15. 15.
    Slater TF, Eakins MN: Interactions of (+)-cyanidanol-3 with free radical generating systems.In New Trends in the Therapy of Liver Diseases. A. Bertelli (ed), Basel, Karger, 1975, pp 84–88Google Scholar
  16. 16.
    Perrissoud D, Weibel I: Protective effect of (+)-cyanidanol-3 in acute liver injury induced by galactosamine or carbon tetrachloride in the rat. Naunyn-Schmiedebergs Arch Pharmacol 312:285–291, 1980Google Scholar
  17. 17.
    Parmar NS, Hennings G: The gastric antisecretory activity of 3-methoxy-5,7,3′,4′-tetrahydroxyflavan (ME)—a specific histidine decarboxylase inhibitor in rats. Agents Actions 15:143–145, 1984Google Scholar
  18. 18.
    Parmar NS, Hennings G, Gluati OP: Histidine decarboxylase inhibition: A novel approach towards the development of an effective and safe gastric antiulcer drug. Agents Actions 15:494–499, 1984Google Scholar
  19. 19.
    Wendt P, Reimann HJ, Swoboda K, Hennings G, Blumel G: The use of flavonoids as inhibitors of histidine decarboxylase in gastric diseases. Experimental and clinical studies. Naunyn-Schmiedeberg's Arch Pharmacol Suppl 313:238, 1980Google Scholar
  20. 20.
    Soll AH, Lewin KJ, Beaven MA: Isolation of histaminecontaining cells from rat gastric mucosa: biochemical and morphological difference from the mast cell. Gastroenterology 80:717–727, 1981Google Scholar
  21. 21.
    Soll AH, Lewin KJ, Beaven MA: Isolation of histaminecontaining cells from canine fundic mucosa. Gastroenterology 77:1283–1290, 1979Google Scholar
  22. 22.
    Lorenz W, Thon K, Barth H, Neugebauer E, Reimann HJ, Kusche J: Metabolism and function of gastric histamine in health and disease. J Clin Gastroenterol 5 (Suppl):37–53, 1983Google Scholar
  23. 23.
    Kahlson G, Rosengren E, Svahn D, Thunberg R: Metabolism and formation of histamine in the gastric mucosa as related to gastric secretion. J Physiol (London) 174:400–416, 1964Google Scholar
  24. 24.
    Bunce KT, Parsons ME, Price CA, Sykes CC: Histidine decarboxylase in the isolated gastric mucosa of the rat. Br J Pharmacol 72:561–562, 1981Google Scholar
  25. 25.
    Guth PH, Ballard KW: Physiology of gastric circulation.In Physiology of the Gastrointestinal Tract. LR Johnson (ed). New York, Raven Press, 1981, pp 709–732Google Scholar
  26. 26.
    Levine RJ, Senay EC: Histamine in pathogenesis of stress ulcer in the rat. Am J Physiol 214:892–896, 1968Google Scholar
  27. 27.
    Schwartz JC, Cohen Y, Valette G: Histidine decarboxylase gastric et ulceres experimentaux chez le rat. Biochem Pharmacol 15:2122–2124, 1966Google Scholar
  28. 28.
    Brodie DA, Chase BJ: Role of gastric acid in aspirin-induced gastric irritation in rats. Gastroenterology 53:604–610, 1967Google Scholar
  29. 29.
    Konturek SJ, Kitler ME, Kwiecien N, Obtulowicz N, Oleksy J, Kopp B: Effect of meciadanol on gastric secretion and aspirin-induced gastric mucosal injury in humans. Scand J Gastroenterol 19:1099–1103, 1984Google Scholar
  30. 30.
    Chaudhury TK, Jacobson ED: Prostaglandin cytoprotection of gastric mucosa. Gastroenterology 74:58–63, 1978Google Scholar
  31. 31.
    Robert A: Prostaglandins and the gastrointestinal tract.In Physiology of the Gastrointestinal Tract, LR Johnson (ed). New York, Raven Press, 1981, pp 1407–1434Google Scholar
  32. 32.
    Konturek SJ: Gastric cytoprotection. Mt Sinai J Med NY 49:355–369, 1982Google Scholar
  33. 33.
    Jayaraj AP, Kitler ME, Tovey FI, Clark CG: The protective effect of a new histidine decarboxylase inhibitor meciadanol (Zy 15029) on experimental ulceration and on mast cell degranulation in several rat models. XII International Congress Gastroenterology. Abstract Book. Lisbon, Portugal, 1984, p 587Google Scholar
  34. 34.
    Rehmann I, Heikel K: Effect of (+)-cyanidanol-3 on the course of acute hepatitis. Med Klin 72:2159–2164, 1977Google Scholar
  35. 35.
    Konturek SJ, Cieszkowski M, Brzozowski T, Piastucki I, Radecki T: Antisecretory and protective effects of 3-O-methyl-catechin (Zy 15029), a specific inhibitor of histidine decarboxylase in animals and in man. Gastroenterology 84:1212, 1983Google Scholar
  36. 36.
    Mundinger GH, Kitler ME, Lamy PP, Zuidema GD: Stressinduced upper GI bleeding: Recognition and treatment. XII International Congress on Gastroenterology. Abstract Book, Lisbon, Portugal, 1984, p 461Google Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • Stanislaw J. Konturek
    • 1
    • 2
  • Mary Ellen Kitler
    • 1
    • 2
  • Tomasz Brzozowski
    • 1
    • 2
  • Tadeusz Radecki
    • 1
    • 2
  1. 1.Institute of PhysiologyAcademy of MedicineKrakowPoland
  2. 2.Experimental TherapeuticsZyma S.A.NyonSwitzerland

Personalised recommendations